Peyronie's Disease (CME)

Journal of Sexual Medicine

Volumn 4, Issue 6, 2007, Pages 1527-1538

  Bella, Anthony J ^a,e   Perelman, Michael A ^b   Brant, William O ^c   Lue, Tom F ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Drug therapy; Natural history; Penis; Peyronie's disease; Surgical therapy

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; CARNITINE; COLCHICINE; COLLAGENASE; CORTICOSTEROID; DEXAMETHASONE; LIDOCAINE; PENTOXIFYLLINE; PLACEBO; TAMOXIFEN; VERAPAMIL;

APPLICATION SITE ERYTHEMA; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; EMOTIONAL STRESS; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; EXTRACORPOREAL LITHOTRIPSY; FAMILY HISTORY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; IONTOPHORESIS; KIDNEY FIBROSIS; MALE GENITAL SYSTEM SURGERY; MEDICAL EDUCATION; MEDLINE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PENIS INJURY; PENIS PROSTHESIS; PEYRONIE DISEASE; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEXUAL INTERCOURSE; SURGICAL APPROACH; TISSUE INJURY;

EID: 35448940929     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00614.x     Document Type: Article

References (42)

1. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson K-E, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, McMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, Saenz de Tejada I, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23.
2. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004;171:2350-3.
3. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int 2001;88:727-30.
4. Greenfield JM, Levine LA. Peyronie's disease: Etiology, epidemiology, and medical treatment. Urol Clin North Am 2005;32:469-78.
5. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006;6:2115-8.
6. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Peyronie's disease. J Sex Med 2004;1:110-5.
7. Jordan GH. Peyronie's disease. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh urology. Philadelphia, PA: Saunders Elsevier; 2007:818-38.
8. Lue TF. Peyronie's disease: An anatomically-based hypothesis and beyond. Int J Impot Res 2002;14: 411-3.
9. Haag SM, Hauck EW, Szardening-Kirchner C, Diemer T, Cha ES, Weidner W, Eickelberg O. Alterations in the transforming growth factor (TGF)-β pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2006;51:255-61.
10. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F, SIMONA Study Group. Peyronie's disease: Prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol 2001;40:525-30.
11. Bella AJ, Sener A, Foell K, Brock GB. Non-palpable scarring of the penile septum as a cause of erectile dysfunction: An atypical form of Peyronie's disease. J Sex Med 2007;4:226-30.
12. Brant WO, Bella AJ, Garcia MM, Tantiwongse K, Dean RC, Lue TF. Isolated septal fibrosis or hematoma-atypical Peyronie's disease? J Urol 2007;177:179-83.
13. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Priapism, Peyronie's disease, penile reconstructive surgery. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, eds. Sexual medicine: Sexual dysfunctions in men and women. Paris: Health Publications; 2004: 399-408.
14. Althof SE, Leiblum SR, Chevert-Measson M, Hartmann U, Levine SB, McCabe M, Plaut M, Rodrigues O, Wylie K. Psychological and interpersonal dimensions of sexual function and dysfunction. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, eds. Sexual medicine: Sexual dysfunctions in men and women. Paris: Health Publications; 2004: 73-115.
15. Peyronie's Disease Society. The Peyronie's Disease Society Welcomes You. Available at: http://www.peyroniessociety.org (accessed July 1, 2007).
16. The Association of Peyronie's Disease Advocates. Your Peyronie's Disease Resource. Available at: http://www.peyroniesassociation.org (accessed July 1, 2007).
17. Ohebshalom M, Mulhall J, Guhring P, Parker M. Measurement of penile curvature in Peyronie's disease patients: Comparison of three methods. J Sex Med 2007;4:199-203.
18. Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006;49:987-97.
19. Levine LA. Medical therapy for Peyronie's disease - State of the Art 2006. J Sex Med 2007;4(1 suppl): 41.
20. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376-9.
21. Pryor JP, Farell CR. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol Med 1983;9:41-5.
22. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (Potaba TM) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-6.
23. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? Urology 2004;44:291-5.
24. Teloken C, Rhoden EL, Grazziotin CT, Da Ros CT, Sogari PR, Souto CAV. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5.
25. Biagotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. BJU Int 2002;89:63-7.
26. Garcia MM, Bella AJ, Lin GT, Lin C-S, Minor TX, Lue TF. The effect of pentoxyfylline on cultured human tunical fibroblasts harvested from patients with Peyronie's disease. Can J Urol 2006; 13: 3099.
27. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002;168:2483.
28. Di Stasi D, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004;171: 740-5.
29. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002;168:621-5.
30. Russell S, Steers W, McVary KT. Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease. Eur Urol 2007;51:640-7.
31. Hellstrom WJG, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough S, Hakim LS, Nehra A, Templeton LE, Pryor JL. Single-blind multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon α-2b for minimally invasive treatment for Peyronie's disease. J Urol 2006;176:394-8.
32. Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J Sex Med 2005;2:709-15.
33. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J Urol 1993;149:56-8.
34. Hatzichristodoulou G, Meisner C, Liske P, Stenzl A, Lahme S. Efficacy of extracorporeal shock wave therapy (ESWT) in patients with Peyronie's disease (PD)-first results of a prospective, randomized, placebo-controlled, single-blind study. J Urol 2006; 175(4 suppl): 320.
35. Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie's disease: A critical analysis. Eur Urol 2006;50:235-48.
36. Lue TF. Surgical therapy for Peyronie's disease. J Sex Med 2007;4(1suppl):42-4.
37. Brant WO, Bella AJ, Lue TF. 16-dot procedure for penile curvature. J Sex Med 2007;4:277-80.
38. Mulhall J, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: Functional and satisfaction outcomes. J Sex Med 2005;2:132-8.
39. Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie's disease surgery: A comprehensive review. J Sex Med 2007;4:581-95.
40. Kovac JR, Brock GB. Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie's disease. J Sex Med 2007; [Epub ahead of print ].
41. Kendirci M, Usta MF, Matern RV, Nowfar S, Sikka SC, Hellstrom WJ. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J Sex Med 2005;2:709-15.
42. Egydio PH, Lucon AM, Arap S. A single relaxing incision to correct different types of penile curvature: Surgical technique based on geometric principles. BJU Int 2004;94:1147-57.